Austin Smith is a GMC-registered physician and pharmaceutical consultant with over 15 years in oncology drug development, dually trained in medical oncology and pharmaceutical medicine. He serves as Chief Medical Officer at Oxcia AB and Head of Clinical Development at Ariceum Therapeutics, leading early-phase and first-in-human programmes across haematological malignancies, radioligand theranostics, and orphan disease. […]
I am a breast medical oncologist, clinical researcher, and academic physician specializing in breast cancer care and clinical trials. As Director of Breast Medical Oncology and Director of the Breast Cancer Clinical Trials Program at MD Anderson Cancer Center at Cooper, I lead efforts to advance innovative treatment strategies and improve outcomes for patients with […]
Mohamed Abozeid, MD PhD, is a Medical Oncologist at The Royal Marsden NHS Foundation Trust, one of the world’s leading cancer centres. He combines clinical practice with academic teaching, serving as a Lecturer and honorary consultant at a faculty of medicine Suez Canal University. He earned his PhD from Padua University following his medical training. […]
Stephen Floor is a subject-matter expert in RNA science and medicine and computational biology with over 15 years of experience spanning academic research and biotechnology. His expertise bridges molecular biology, RNA biology, and computational approaches to understanding gene expression and developing RNA-based therapeutics.nnHe earned his PhD from UCSF in 2011, where he has built deep […]
Ray Stevens is a biotech executive, company builder, and drug development operator with experience across CMC, IND strategy, translational development, clinical planning, commercialization, financing, and fundraising strategy. He helps early and mid stage life sciences companies convert complex science into credible, executable development plans. Ray works with teams to clarify the next highest value experiment, […]
20+ years in academia (basic and clinical research, education) 20+ years in pharma in development at BMS and NovoNordisk, then member of the Global Therapeutic Area Leadership at PAREXEL, most recently as an independent consultant to small and medium biopharma and pharma, especially working with early development on CDPs and protocol development, from scientific background […]